In an unprecedented breakthrough in the realm of targeted therapies, Zymeworks’ zanidatamab has procured conditional approval in China as the inaugural dual HER2-targeted bispecific antibody. This game-changing drug is specifically designed to combat HER2-high expression (IHC3+) biliary tract cancer (BTC), a particularly aggressive form of cancer with few effective treatment options. This milestone was realized […]